PBK/TOPK as a Potential Therapeutic Target in Glioblastoma and Other MalignanciesBiljana Stangeland*
Norwegian Center for Stem Cell Research, Department of Immunology, Oslo University Hospital, 4950 Nydalen 0424 Oslo, Norway
- *Corresponding Author:
- Biljana Stangeland
Department of Molecular Medicine, Institute of Basic Medical Sciences
The Medical Faculty, University of Oslo, Oslo, Norway
E-mail: [email protected]
Received date: December 22, 2015; Accepted date: December 27, 2015; Published date: January 09, 2016
Citation: Stangeland B (2016) PBK/TOPK as a Potential Therapeutic Target in Glioblastoma and Other Malignancies. Mol Biol 5:151. doi: 10.4172/2168-9547.1000151
Copyright:© 2016 Stangeland B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A serine/threonine kinase PDZ binding-kinase (PBK) is a member of the mitogen-activated protein kinase (MAPK) kinase (MAPKK) family. This enzyme is also known under the name T-lymphokine-activated killer cell-originated protein kinase (TOPK). PBK was discovered as a factor that binds PDZ2 domain of hDLg (human homologue of the Drosophila Discs-large (Dlg) tumor suppressor protein).This study also demonstrated that the mitotic phosphorylation of PBK is required for its kinase activity.